RankAlpha logo
Back to Rankings

OKUR

OnKure TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart

Operating peers and competitors

Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.

Loading market evidence...

Research comparisons do not establish forecast usefulness or trading returns.

Compare shared product markets

Membership only; no portfolio weights or estimated losses.

+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
OKUR vs peer average
50/100
OKUR vs. peer average (D vs. D)
Grade spread
B 2 · C 2 · F 6
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

RLAY is the first available peer comparator.

Relay's zovegalisib is a mutant-selective PI3Kα program studied in both breast cancer and vascular anomalies, making it a direct scientific benchmark. Its breast-cancer program is already in Phase 3, far ahead of OnKure's planned IND submissions, so its equity valuation is not directly transferable. Source: https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announces-data-zovegalisib-fulvestrant-phase

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerRLAYRelay Therapeutics
OKUR
OnKure Therapeutics
RLAY
Relay Therapeutics
Grade
D
F
Momentum
43
74
Value
56
41
Sentiment
29
26
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Open Side-by-Side ComparisonCompare top peers (up to 3)

Grade position vs RLAY

OKUR / RLAY
Grade Position
In line
OKUR vs. peer average (D vs. D)
50/100
Momentum
43
RLAY
Value
56
OKUR
Sentiment
29
OKUR

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs OKUR
1
RLAY
RLAY
F
20/100
-1
2
NVS
NVS
B
80/100
+2
3
BGM
BGM Group Ltd Class A Common
F
20/100
-1
4
IMUX
Immunic Inc Common
F
20/100
-1
5
VTVT
vTv Therapeutics Inc Class A Common
B
80/100
+2
RLAY is the first peer returned for this comparison set.